Complex Generic Approval Delays Getting Congressional Attention

 
• By Derrick Gingery
Capitol Building, Washington DC
A bipartisan group of House Energy and Commerce Committee members want information from FDA on complex generic approvals, potentially to consider ways of streamlining the process.

More from Generics

More from Biosimilars & Generics